|1.||Terpos, Evangelos: 14 articles (11/2011 - 08/2003)|
|2.||Dougall, William C: 11 articles (01/2015 - 11/2002)|
|3.||Kostenuik, Paul J: 8 articles (12/2015 - 10/2005)|
|4.||Ueland, Thor: 8 articles (06/2010 - 07/2002)|
|5.||Schwarz, Edward M: 7 articles (12/2014 - 03/2002)|
|6.||Lewiecki, E Michael: 7 articles (01/2011 - 07/2006)|
|7.||Aukrust, Pål: 7 articles (06/2010 - 05/2005)|
|8.||Hofbauer, L C: 7 articles (01/2004 - 01/2000)|
|9.||Saad, Fred: 6 articles (10/2013 - 05/2008)|
|10.||Reddy, Sakamuri V: 6 articles (09/2013 - 03/2004)|
|1.||Neoplasm Metastasis (Metastasis)
01/01/2012 - "In preclinical studies, RANK Ligand inhibition has been shown to prevent the development of bone and some visceral metastases. "
05/01/2015 - "However, extensive metastasis was observed in functionalized scaffolds, and the highest levels for scaffolds that were in situ manipulated with receptor activator of nuclear factor kappa-B ligand (RANKL). "
02/01/2014 - "RANK ligand (RANKL), acting through its cognate receptor RANK, is a key factor for bone remodeling and metastasis by regulating the differentiation, survival and activation of osteoclasts. "
11/01/2013 - "[Inhibition of RANK ligand to treat bone metastases]."
10/01/2013 - "Receptor activator of nuclear factor-κB (RANK) and RANK ligand (RANKL) belong to a signal pathway highly implicated in the development of bone metastases. "
03/01/2002 - "Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors."
12/01/2015 - "Rank ligand as a target in musculoskeletal neoplasms."
10/20/2012 - "Bisphosphonate therapy and rank-ligand monoclonal antibody therapy are the most commonly used agents for management of bone loss resulting from cancer treatment. "
11/15/2011 - "Infiltration of tumors by regulatory T cells confers growth and metastatic advantages by inhibiting antitumor immunity and by production of receptor activator of NF-κB (RANK) ligand, which may directly stimulate metastatic propagation of RANK-expressing cancer cells. "
11/04/2010 - "Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer."
|3.||Prostatic Neoplasms (Prostate Cancer)
01/01/2009 - "Expression of RANK-ligand in prostate cancer cell lines."
09/01/2012 - "Denosumab, a fully human monoclonal antibody against RANK ligand, increased bone mineral density (BMD) and reduced fracture risk vs placebo in a phase 3 trial in men with prostate cancer on androgen deprivation therapy (ADT). "
09/01/2011 - "A large randomized trial of denosumab, an antibody to RANK ligand, in prostate cancer has demonstrated prevention of bone loss and a reduction in fractures. "
03/01/2011 - "The purpose of this study was to investigate the influence of combined inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) and bone morphogenetic protein (BMP) activity in a mixed lytic/blastic prostate cancer lesion in bone. "
01/01/2011 - "Studies that analyze the levels of osteoprotegerin (OPG) or receptor activator of nuclear factor kappa B ligand (RANKL) in hypogonadal men, the majority of whom have prostate cancer or are undergoing androgen-deprivation therapy, are few and inconclusive. "
12/01/2015 - "The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis."
06/01/2015 - "The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis."
08/01/2011 - "From the recent results of several kinds of knockout mice, osteoclast differentiation factor (RANKL) and its soluble decoy receptor for RANKL (OPG) are essentially involved in pathogenesis of osteoporosis. "
10/01/2010 - "The first inhibitor of RANK-ligand for treatment of osteoporosis]."
01/01/2002 - "Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis."
|5.||Bone Diseases (Bone Disease)
04/01/2003 - "Recent studies showed that the receptor activator of nuclear factor kappaB ligand (RANKL) is the key mediator of osteoclastogenesis and plays a crucial role in bone destruction in malignant bone disease. "
06/01/2014 - "Receptor activator of nuclear factor-κB (RANK) and RANK ligand (RANKL) play a pivotal role in bone metabolism, and selective targeting of RANK signaling has become a promising therapeutic strategy in the management of resorptive bone diseases. "
12/01/2009 - "Receptor activator of nuclear factor-kappaB ligand (RANKL) plays a key role in osteoclast activation in myeloma bone disease. "
04/01/2010 - "Recently, a new class of agents targeting the receptor activator of nuclear factor-kappaB ligand (RANKL) pathway has been developed for the treatment of osteoporosis and other bone diseases. "
12/01/2009 - "In cancer-induced bone disease, for example, RANK ligand overwhelms the effects of OPG, leading to imbalanced bone remodeling and the "vicious cycle" of metastatic disease. "
|2.||zoledronic acid (zoledronate)
|7.||Selective Estrogen Receptor Modulators (SERM)
|3.||Hip Replacement Arthroplasty (Total Hip Replacement)
|4.||Heterologous Transplantation (Xenotransplantation)